These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7709707)

  • 1. [Bone manifestations of multiple myeloma and therapeutic possibilities].
    Adam Z; Vorlícek J
    Acta Med Austriaca; 1994; 21(5):117-21. PubMed ID: 7709707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for osteoporosis.
    Med Lett Drugs Ther; 1996 Jan; 38(965):1-3. PubMed ID: 8551978
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium fluoride treatment of bone disease in multiple myeloma.
    Gardner FH
    Tex Med; 1984 Dec; 80(12):28-30. PubMed ID: 6096981
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of primary osteoporosis in men].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2006 Mar; 16(3):474-9. PubMed ID: 16508131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of osteoporosis: current data and prospects].
    Reginster JY; Deroisy R; Franchimont P
    Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):155S-164S. PubMed ID: 7858567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.
    Kyle RA; Jowsey J; Kelly PJ; Taves DR
    N Engl J Med; 1975 Dec; 293(26):1334-8. PubMed ID: 1102987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteoporosis in multiple myeloma].
    Sakalová A; Herrmann Z; Gazová S; Chabronová I; Dedík L; Mistrík M; Hrubisko M
    Vnitr Lek; 1998 Nov; 44(11):649-53. PubMed ID: 10422504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM; Ste-Marie LG
    CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.